CTS Corp banner

CTS Corp
F:XT1

Watchlist Manager
CTS Corp Logo
CTS Corp
F:XT1
Watchlist
Price: 48.8 EUR 0.41% Market Closed
Market Cap: €1.5B

CTS Corp
Investor Relations

CTS Corp makes electronic components and sensors that help equipment measure, control, and connect signals. Its products include things like sensors, frequency control parts, and other precision components used inside larger systems rather than sold to consumers on their own. The company is mainly a parts supplier to industrial, automotive, aerospace, medical, and communications customers that need reliable components designed to fit specific technical requirements. CTS sells these parts to original equipment makers and other manufacturers that build them into finished products. It makes money by designing, manufacturing, and shipping these components, often in long-term supply relationships where customers depend on CTS for technical support, quality control, and consistent production. Because many of its products are engineered to customer specifications, the company is less of a commodity seller and more of a specialized supplier embedded in the customer’s design process. That role matters because CTS sits in the middle of the electronics value chain: it does not make finished cars, medical devices, or industrial machines, but it provides the sensing and control pieces those products need to work properly. This gives the business a mix of manufacturing know-how and engineering expertise, with demand tied to industries that need compact, dependable electronic parts.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
Apr 29, 2026
AI Summary
Q1 2026

Sales and EPS beat: CTS reported first-quarter sales of $139 million, up 11% year over year, with adjusted diluted EPS of $0.62 versus $0.44 last year. Management said no revenue was pulled forward into the quarter.

Mix helped margins: Gross margin expanded by 250 basis points to 39.5%, helped by better end-market mix and operational improvements, especially in the higher-margin diversified businesses.

Diversification is working: Diversified end-market sales rose 18% and management said the company is seeing improved earnings quality as it shifts further away from transportation.

Guidance narrowed: For full-year 2026, CTS narrowed sales guidance to $560 million to $580 million and adjusted diluted EPS to $2.35 to $2.45.

Medical strength: Medical sales rose 28% to $25 million, bookings were up 18%, and management said demand remains strong in therapeutics, diagnostics, and aesthetics, with capacity being expanded ahead of demand.

Transportation cautious: Transportation sales rose 3% in the quarter, but management still expects full-year production volumes to be down, citing geopolitical uncertainty, softer light-vehicle volumes, and supply-chain risks.

Cash and capital returns: CTS generated $17 million of operating cash flow, ended the quarter with $91 million of cash, and returned $10 million to shareholders through dividends and buybacks.

Key Financials
Sales
$139 million
Book-to-bill ratio
1.1
Medical sales
$25 million
Medical book-to-bill ratio
1.2
Aerospace and defense sales
$17 million
Industrial sales
$37 million
Industrial book-to-bill ratio
1.29
Gross margin
39.5%
Adjusted diluted EPS
$0.62
Diluted EPS
$0.59
Operating cash flow
$17 million
Cash balance
$91 million
Borrowings
$63 million
Share repurchases
177,000 shares
Share repurchase spending
approximately $9 million
Returned to shareholders
$10 million
Remaining share repurchase authorization
$82 million
Foreign currency impact on sales
$3 million
Foreign currency impact on gross margin
$700,000
Tax rate
20.7%
Booked business backlog
approximately $1.1 billion
Earnings Call Recording
Other Earnings Calls

Management

Mr. Kieran M. O'Sullivan
Chairman, President & CEO
No Bio Available
Mr. Ashish Agrawal
VP, CFO & Principal Accounting Officer
No Bio Available
Mr. Scott L. D'Angelo
VP, General Counsel & Secretary
No Bio Available
Mr. Mitchell J. Walorski
Director of Investor Relations
No Bio Available
Pratik Trivedi
Senior Vice President
No Bio Available

Contacts

Address
ILLINOIS
Lisle
4925 Indiana Ave
Contacts
+16305778800.0
www.ctscorp.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett